AstraZeneca Maintains 2025 Forecast as U.S. Pharma Tariffs Align With Other Sectors

LONDON (Cryptonesia) – The CEO of AstraZeneca stated on Tuesday that the company plans to uphold its 2025 revenue forecast despite potential U.S. tariffs on pharmaceutical goods manufactured within the European Union, as long as these duties align with those imposed on other industries.

While discussing with reporters during a conference call, Pascal Soriot mentioned the firm’s quarterly performance where earnings fell short of analysts' projections, causing the stock price to drop over 4%.

(Reported by Maggie Fick and Pushkala Aripaka, Edited by Louise Heavens)